AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31217024 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio advertising
Number of subjects: 1007
Study 31217024 — intervention group
Group type: EXPERIMENTAL
Intervention: Newspaper advertising
Number of subjects: 1007
Study 30400977 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil combined with dexmedetomidine
Number of subjects: 354
Study 30400977 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drugs (urapidil, nicardipine, labetalol)
Number of subjects: 354
Study 26528774 — intervention group
Group type: EXPERIMENTAL
Intervention: New Helmet (NH)
Number of subjects: 14
Study 26528774 — intervention group
Group type: COMPARATOR
Intervention: Standard Helmet (SH)
Number of subjects: 14
Study 26528774 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube
Number of subjects: 14
Study 24460688 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration with ICON and varnished with Duraphat (I+F)
Number of subjects: 50
Study 24460688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed with Delton and varnished with Duraphat (S+F)
Number of subjects: 50
Study 24460688 — intervention group
Group type: COMPARATOR
Intervention: Only varnished with Duraphat (F)
Number of subjects: 50
Study 22439868 — intervention group
Group type: EXPERIMENTAL
Intervention: SkinDoctor(®) fabric
Number of subjects: 12
Study 22439868 — intervention group
Group type: COMPARATOR
Intervention: 100% cotton
Number of subjects: 12
Study 20113961 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser zona thinning
Number of subjects: 400
Study 20113961 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated zona pellucida)
Number of subjects: 400
Study 18476430 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuetong Injection (SXTI) high dose (8 mL/d)
Number of subjects: 97
Study 18476430 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuetong Injection (SXTI) low dose (6 mL/d)
Number of subjects: 97
Study 18476430 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 97
Study 15546907 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid iv, administered as three monthly doses
Number of subjects: 32
Study 15546907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 32
Study 12055562 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless bioprosthesis
Number of subjects: 28
Study 12055562 — intervention group
Group type: COMPARATOR
Intervention: Stented bioprosthesis
Number of subjects: 28
Study 10530684 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 3600 mg per day)
Number of subjects: 0
Study 10530684 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 10530684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7722692 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast
Number of subjects: 197
Study 7722692 — intervention group
Group type: COMPARATOR
Intervention: Quarter of an orange (placebo)
Number of subjects: 197
Study 3047380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 400 mg daily
Number of subjects: 162
Study 3047380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 600 mg daily
Number of subjects: 162
Study 31740860 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning
Number of subjects: 80
Study 31740860 — intervention group
Group type: COMPARATOR
Intervention: Facilitator-assisted learning
Number of subjects: 80
Study 28124206 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% NAC
Number of subjects: 120
Study 28124206 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% NAC + 0.5% glycine
Number of subjects: 120
Study 28124206 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC
Number of subjects: 120
Study 28124206 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 28124206 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% glycine
Number of subjects: 120
Study 26032168 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (80 mg)
Number of subjects: 9
Study 26032168 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (30 mg)
Number of subjects: 9
Study 26032168 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine and Oxycodone (80 mg and 30 mg respectively)
Number of subjects: 9
Study 26032168 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 9
Study 23530757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular magnesium sulphate regimen
Number of subjects: 300
Study 23530757 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium sulphate regimen
Number of subjects: 300
Study 20669228 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling kit
Number of subjects: 4160
Study 20669228 — intervention group
Group type: COMPARATOR
Intervention: Reminder letter
Number of subjects: 4160
Study 20669228 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling kit and Reminder letter
Number of subjects: 4160
Study 18458874 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-circuit ventilators with plateau valve at helmet expiratory port
Number of subjects: 10
Study 18458874 — intervention group
Group type: COMPARATOR
Intervention: Closed-circuit ventilator (helmet CPAP and pressure support ventilation)
Number of subjects: 10
Study 22059194 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR (50 mg or 100 mg every 4 to 6 hours as needed)
Number of subjects: 849
Study 22059194 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone IR (10 mg or 15 mg every 4 to 6 hours as needed)
Number of subjects: 849
Study 22059194 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR
Number of subjects: 849
Study 22059194 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone IR
Number of subjects: 849
Study 16272183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2mg
Number of subjects: 18
Study 16272183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11968154 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb CD18 (0.06, 0.12, 0.25, 0.5, 1.0, 2.0 mg/kg)
Number of subjects: 53
Study 11968154 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb CD18 (doses above 0.06 mg/kg)
Number of subjects: 53
Study 11968154 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb CD18
Number of subjects: 53
Study 9893888 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence Based Emergency Medicine (EBEM) practices
Number of subjects: 0
Study 9893888 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled studies
Number of subjects: 0
Study 9893888 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures without proven scientific evidence
Number of subjects: 0
Study 7923513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral popliteal sciatic nerve block (group PS)
Number of subjects: 40
Study 7923513 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous infiltration (group SC)
Number of subjects: 40
Study 3072446 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-anginal therapy
Number of subjects: 0
Study 12410124 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide preperitoneal mesh
Number of subjects: 0
Study 12410124 — intervention group
Group type: COMPARATOR
Intervention: Small onlay mesh prostheses
Number of subjects: 0
Study 30159789 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (O3-FA)
Number of subjects: 249
Study 30159789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 27494257 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary finger extension (Fugl-Meyer Assessment hand sub item finger extension≥1)
Number of subjects: 100
Study 27494257 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of voluntary finger extension
Number of subjects: 100
Study 27494257 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb capacity
Number of subjects: 100
Study 24510005 — intervention group
Group type: EXPERIMENTAL
Intervention: Brilliant Blue G (BBG) applied at 0.2 mL for 2 minutes under air conditions during ERM surgery
Number of subjects: 21
Study 23422602 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% Natrium‐Fluoride‐containing artificial saliva at pH 4 for three days
Number of subjects: 0
Study 23422602 — intervention group
Group type: COMPARATOR
Intervention: 0% Natrium‐Fluoride‐containing artificial saliva at pH 4 for three days
Number of subjects: 0
Study 23422602 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% Natrium‐Fluoride‐containing artificial saliva at pH 6
Number of subjects: 0
Study 23422602 — intervention group
Group type: COMPARATOR
Intervention: 0% Natrium‐Fluoride‐containing artificial saliva at pH 6
Number of subjects: 0
Study 19081443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 20
Study 19081443 — intervention group
Group type: COMPARATOR
Intervention: Education Control
Number of subjects: 20
Study 16202043 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (LILT) with infrared laser (780 nm, 30 mW, 10 s, 6.3 J/cm(2))
Number of subjects: 30
Study 16202043 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (LILT)
Number of subjects: 30
Study 16202043 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 30
Study 12076869 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU of interferon alpha 2b combined with ribavirin (1000-1200 mg daily)
Number of subjects: 298
Study 12076869 — intervention group
Group type: COMPARATOR
Intervention: 3 MU of interferon alpha 2b combined with ribavirin (1000-1200 mg daily)
Number of subjects: 298
Study 9988394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertilization antigen (FA)‐1
Number of subjects: 18
Study 9988394 — intervention group
Group type: COMPARATOR
Intervention: Control medium
Number of subjects: 18
Study 7645613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section
Number of subjects: 200
Study 7645613 — intervention group
Group type: COMPARATOR
Intervention: Trial of labor
Number of subjects: 200
Study 2141612 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (average daily dose 269 mg, range 150 to 300)
Number of subjects: 34
Study 2141612 — intervention group
Group type: COMPARATOR
Intervention: Minoxidil (average daily dose 20 mg, range 7.5 to 30)
Number of subjects: 34
Study 580588 — intervention group
Group type: EXPERIMENTAL
Intervention: meproscillarin
Number of subjects: 10
Study 580588 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 31054907 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling
Number of subjects: 497
Study 31054907 — intervention group
Group type: COMPARATOR
Intervention: Clinician-based sampling
Number of subjects: 497
Study 28542003 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice exercise condition
Number of subjects: 58
Study 28542003 — intervention group
Group type: COMPARATOR
Intervention: No-choice exercise condition
Number of subjects: 58
Study 25735993 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.0 mg/kg)
Number of subjects: 32
Study 25735993 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (0.5 mg/kg)
Number of subjects: 32
Study 25735993 — intervention group
Group type: COMPARATOR
Intervention: No drug administration (Study 1)
Number of subjects: 32
Study 23909121 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O‐O2 mixture (Inspired O2 30%)
Number of subjects: 30
Study 23909121 — intervention group
Group type: COMPARATOR
Intervention: Air‐oxygen mixture (Inspired O2 50%)
Number of subjects: 30
Study 21954280 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (OC) treatment
Number of subjects: 442
Study 21954280 — intervention group
Group type: EXPERIMENTAL
Intervention: No oral contraceptive (non-OC) treatment
Number of subjects: 442
Study 19184101 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 30
Study 19184101 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 30
Study 17143257 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with chemotherapy (paclitaxel plus carboplatin)
Number of subjects: 0
Study 17143257 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with erlotinib
Number of subjects: 0
Study 17143257 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 17143257 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antiangiogenic approaches (small‐molecule tyrosine kinase inhibitors)
Number of subjects: 0
Study 14656690 — intervention group
Group type: EXPERIMENTAL
Intervention: IC14 (anti-CD14 monoclonal antibody)
Number of subjects: 16
Study 14656690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10782603 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-hospital interventions
Number of subjects: 285
Study 8997058 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐X Block (n = 100)
Number of subjects: 200
Study 8997058 — intervention group
Group type: COMPARATOR
Intervention: Gum bite block (n = 100)
Number of subjects: 200
Study 8997058 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐X Block (n = 20)
Number of subjects: 200
Study 1284161 — intervention group
Group type: EXPERIMENTAL
Intervention: GSR 100 mg
Number of subjects: 12
Study 1284161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6741684 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment joiners
Number of subjects: 108
Study 6741684 — intervention group
Group type: COMPARATOR
Intervention: Non-joiners
Number of subjects: 108
Study 30216275 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ simulation (ISS)
Number of subjects: 73
Study 30216275 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitigation strategies
Number of subjects: 73
Study 30086780 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised exercise programme and behaviour change counselling (12-week duration, includes up to five in-person counselling sessions and written materials)
Number of subjects: 0
Study 30086780 — intervention group
Group type: COMPARATOR
Intervention: Usual care as recommended by evidence-based guidelines
Number of subjects: 0
Study 26959690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pascal® Photocoagulator (PP)
Number of subjects: 80
Study 26959690 — intervention group
Group type: COMPARATOR
Intervention: Conventional Argon Laser Photocoagulator (CALP)
Number of subjects: 80
Study 24493633 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily crossword intervention for 4 weeks
Number of subjects: 37
Study 24493633 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily gratitude diary for 4 weeks)
Number of subjects: 37
Study 22471295 — intervention group
Group type: EXPERIMENTAL
Intervention: SLCaps (soft gelatin capsules)
Number of subjects: 34
Study 22471295 — intervention group
Group type: EXPERIMENTAL
Intervention: HPCaps (hard gelatin capsules)
Number of subjects: 34
Study 22471295 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vinflunine
Number of subjects: 34
Study 22471295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral formulations (SLCaps and HPCaps)
Number of subjects: 34
Study 21198252 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Day Training
Number of subjects: 62
Study 21198252 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced Training
Number of subjects: 62
Study 21198252 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Mental Rotation Training, MRT and FLS
Number of subjects: 62
Study 21198252 — intervention group
Group type: EXPERIMENTAL
Intervention: MRT and FLS
Number of subjects: 62
Study 21198252 — intervention group
Group type: COMPARATOR
Intervention: FLS‐only
Number of subjects: 62
Study 17435527 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 154
Study 17435527 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study 17435527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study 16291601 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 2859
Study 16291601 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) with clopidogrel and standard fibrinolytic and aspirin
Number of subjects: 2859
Study 11858203 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide in sterile saline
Number of subjects: 43
Study 11858203 — intervention group
Group type: COMPARATOR
Intervention: Gutta-percha and AH-26 sealer
Number of subjects: 43
Study 9526191 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 7725867 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.5 mg/kg with epinephrine (14 patients)
Number of subjects: 30
Study 7725867 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 0.5 mg/kg without epinephrine (16 patients)
Number of subjects: 30
Study 2639069 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.1% mouth rinse for 2 minutes
Number of subjects: 0
Study 2639069 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution mouth rinse
Number of subjects: 0
Study 823563 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 0
Study 823563 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazepam
Number of subjects: 0
Study 823563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28386788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load AECT
Number of subjects: 23
Study 28386788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load AECT
Number of subjects: 23
Study 28386788 — intervention group
Group type: COMPARATOR
Intervention: Compression-only therapy (CT)
Number of subjects: 23
Study 27413670 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT program (technology-assisted goal setting)
Number of subjects: 54
Study 25271534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) applied using otowick
Number of subjects: 47
Study 25271534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) applied using cottonoids
Number of subjects: 47
Study 25271534 — intervention group
Group type: COMPARATOR
Intervention: Normal saline applied using otowick
Number of subjects: 47
Study 25271534 — intervention group
Group type: COMPARATOR
Intervention: Normal saline applied using cottonoids
Number of subjects: 47
Study 22916209 — intervention group
Group type: EXPERIMENTAL
Intervention: MUP-CHX (n=210)
Number of subjects: 415
Study 22916209 — intervention group
Group type: EXPERIMENTAL
Intervention: MUP-CHX in cardiothoracic patients (n=280)
Number of subjects: 415
Study 22916209 — intervention group
Group type: EXPERIMENTAL
Intervention: MUP-CHX in orthopaedic patients (n=135)
Number of subjects: 415
Study 22916209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=205)
Number of subjects: 415
Study 19443914 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency based virtual reality simulator training in laparoscopic salpingectomy
Number of subjects: 24
Study 19443914 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical education (controls)
Number of subjects: 24
Study 17313717 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prohepcidin concentration in healthy men
Number of subjects: 187
Study 17313717 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prohepcidin concentration in hereditary haemochromatosis patients
Number of subjects: 187
Study 17313717 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prohepcidin concentration in pregnant women
Number of subjects: 187
Study 17313717 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron absorption efficiency
Number of subjects: 187
Study 17313717 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prohepcidin concentration and serum ferritin relationship
Number of subjects: 187
Study 15449742 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2-5 mg kg(‐1) h(‐1))
Number of subjects: 22
Study 15449742 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1-2%)
Number of subjects: 22
Study 11405491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 22
Study 11405491 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 9754479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 20 mg orally (dose 1) and 10 mg (dose 2)
Number of subjects: 125
Study 9754479 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone 10 mg plus acetaminophen 1,000 mg orally (both doses)
Number of subjects: 125
Study 8313331 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB486IL-2 at 0.2 mg/kg daily for 5 days
Number of subjects: 15
Study 8313331 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB486IL-2 at 0.075 mg/kg and 0.115 mg/kg
Number of subjects: 15
Study 8313331 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB486IL-2
Number of subjects: 15
Study 3416497 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP) at doses of 0.1 and 0.33 mg/kg three times daily
Number of subjects: 16
Study 3416497 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP) at high dose
Number of subjects: 16
Study 1960623 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 10
Study 1960623 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium
Number of subjects: 10
Study 1070466 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapy (BCG and irradiated allogeneic myeloblastic leukaemia cells)
Number of subjects: 52
Study 1070466 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 52
Study 1070466 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapy
Number of subjects: 52
Study 31618328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyldiguanide combined with clomifene citrate
Number of subjects: 79
Study 31618328 — intervention group
Group type: COMPARATOR
Intervention: Clomifene citrate alone
Number of subjects: 79
Study 28741683 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel oily emulsion
Number of subjects: 40
Study 28741683 — intervention group
Group type: COMPARATOR
Intervention: Methylcellulose
Number of subjects: 40